Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06365619
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-15
First Post:
2024-04-09
Brief Title:
Neoadjuvant IpilimumabNivolumab for Patients With Recurrent High Risk Resectable Melanoma
Sponsor:
University of Utah
Organization:
University of Utah
Study Overview
Official Title:
Phase II Study of Neoadjuvant IpilimumabNivolumab for Patients With Recurrent High Risk Resectable Melanoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NeoRelapse
Brief Summary:
The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy
Participants will receive 2 cycles of treatment prior to their standard of care surgery After surgery participants will receive standard of care adjuvant therapy and be followed for response
Participants will receive 2 cycles of treatment prior to their standard of care surgery After surgery participants will receive standard of care adjuvant therapy and be followed for response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None